This article is for informational purposes only and does not constitute medical advice. All pricing and service information is based on publicly available sources as of April 2026 and is subject to change. This publication has no affiliation with any platform discussed. Consult a qualified healthcare professional before starting any medication.

Choosing a GLP-1 Telehealth Platform in 2026: How Direct Meds Compares to Hims, Ro, Henry Meds, and MEDVi on Pricing, Safety, and Clinical Oversight

The compounded GLP-1 telehealth market in 2026 is crowded and competitive. Dozens of platforms now offer some variation of compounded semaglutide or tirzepatide at prices well below brand-name Wegovy and Mounjaro, and the marketing claims look remarkably similar across all of them. But the differences that actually matter — clinical oversight quality, compounding pharmacy standards, billing transparency, cancellation policies, and regulatory compliance — aren't visible from the homepage. This comparison evaluates five of the most prominent platforms side by side, using the factors that directly affect patient safety and treatment outcomes.

The Platforms Being Compared

Direct Meds (directmeds.com) is a LegitScript-certified telehealth platform based in Utah, offering compounded semaglutide and tirzepatide in both injectable and sublingual oral formats. The company partners with CraftedRx and ChemistryRx, both 503A compounding pharmacies. According to various third-party sources, the platform has served over 53,000 to 180,000 customers. Direct Meds' customer support line can be reached at (888) 696-7176 — the Direct Meds phone number most frequently referenced in reviews. For our full clinical evaluation, see our full Direct Meds review.

Hims & Hers (hims.com / forhers.com) is a publicly traded telehealth company offering a broader range of health services alongside its GLP-1 program. Hims provides compounded semaglutide with the option to include lozenge or injectable formats. The platform also received an FDA warning letter in September 2025 as part of the same mass enforcement action that targeted Direct Meds.

Ro (ro.co) is a venture-backed telehealth platform that offers both brand-name and compounded GLP-1 options. Ro's model includes a membership fee structure on top of medication costs, and the platform provides stronger clinical support including metabolic health coaching and body composition tracking.

Henry Meds (henrymeds.com) has positioned itself as the budget-friendly entry point to compounded GLP-1 therapy, with advertised semaglutide pricing starting at $99 per month. The platform uses an asynchronous consultation model and partners with 503A compounding pharmacies.

MEDVi (medvhealth.com) operates a broader telehealth platform covering GLP-1 weight management, ED treatment, and other specialties. The company has a substantial press presence and a more clinically detailed intake process than some competitors. For readers who've seen our previous coverage, this is the same platform evaluated in the HealthDataConsortium.org MEDVi telehealth review.

Pricing Comparison: What You'll Actually Pay Monthly

Pricing in the compounded GLP-1 space is notoriously difficult to compare apples-to-apples because platforms structure costs differently — some bundle everything, others layer fees.

Direct Meds tirzepatide cost starts at approximately $349 to $497 per month depending on the plan and any active promotions. Semaglutide starts at approximately $197 to $297 per month. These prices are all-inclusive — medication, supplies, telehealth consultations, and free 1-2 day shipping are bundled with no separate membership fee. This transparency is one of the platform's genuine differentiators.

Hims advertises compounded semaglutide starting around $199 per month, though some plan tiers and dose levels run higher. Hims doesn't charge a separate membership fee for its GLP-1 program specifically, but the overall cost structure can vary by state and dosing.

Ro uses a membership model — approximately $145 per month for program membership, with medication costs on top. The total monthly cost can exceed $300 to $400 depending on the medication and dose, but the clinical support infrastructure is more thorough than most competitors.

Henry Meds' $99 per month semaglutide starting price is the most aggressively positioned in the market. Whether that introductory rate applies at therapeutic doses or only during the initial low-dose titration phase is worth confirming before enrolling, as some platforms advertise starting-dose pricing while the therapeutic-dose cost is substantially higher.

MEDVi's pricing starts around $179 per month for semaglutide programs. The company positions itself as offering more clinical depth than the purely affordability-focused competitors. For readers evaluating MEDVi specifically alongside other GLP-1 options, our MEDVi vs. Hims vs. Ro GLP-1 comparison covers that platform's positioning in additional detail.

For context, brand-name Wegovy runs approximately $1,349 per month without insurance, and Zepbound exceeds $1,000 monthly. The entire compounded GLP-1 telehealth segment exists because these brand-name prices are prohibitive for the vast majority of uninsured patients.

Clinical Oversight: Where the Real Differences Emerge

The factor that most directly affects patient safety and treatment outcomes is the quality and depth of clinical oversight — and this is where the platforms diverge most meaningfully.

Direct Meds uses an asynchronous model where providers review written intake forms. The company includes nurse support in its plans, which provides a channel for ongoing side-effect management and dosing questions. The LegitScript certification adds a layer of independent compliance verification. However, the lack of live video consultations means the initial clinical assessment is less thorough than what a synchronous model provides.

Hims offers both asynchronous and synchronous consultation options depending on the program tier. The platform has invested heavily in its clinical infrastructure as a public company, though its GLP-1 program has seen some of the same FDA scrutiny as Direct Meds.

Ro stands out for clinical depth. The platform offers metabolic health coaching, body composition tracking tools, and a more structured follow-up cadence. The membership fee structure reflects this — you're paying more because the clinical support infrastructure costs more to operate. For patients with complex medical histories or those who want a more hands-on clinical experience, Ro's model addresses concerns that asynchronous-only platforms don't.

Henry Meds at its price point delivers a fairly basic service — prescription access is the primary value proposition, with limited ongoing clinical support. For straightforward GLP-1 candidates who primarily need affordable medication access, this may be sufficient. For patients who need more clinical guidance, the savings may come at a cost in terms of oversight.

MEDVi positions itself between the budget tier and the premium tier, with a more detailed intake process than the lowest-cost competitors and some ongoing support infrastructure.

Compounding Quality and Pharmacy Partners

All five platforms use U.S.-based compounding pharmacies, which is the baseline expectation. The differentiation comes in transparency about which pharmacies are being used and what quality controls they maintain.

Direct Meds names its pharmacy partners — CraftedRx and ChemistryRx — and publishes purity analysis documents for its semaglutide and tirzepatide formulations. This level of transparency is above average for the space. Ro and Hims, as larger companies, work with a broader network of compounding partners and have the resources to maintain quality oversight across their pharmacy network. Henry Meds and MEDVi provide less public detail about their specific pharmacy partners, which isn't necessarily a concern but does make independent verification harder for patients.

For a deeper discussion of how compounding quality affects treatment outcomes, see our article on what to evaluate when your GLP-1 medication isn't working.

Regulatory Compliance and FDA History

Both Direct Meds and Hims received FDA warning letters in September 2025 as part of a mass enforcement action targeting approximately 55 telehealth companies for marketing claims about compounded GLP-1 medications. The letters specifically addressed language that implied compounded products were equivalent to FDA-approved drugs. Neither letter alleged medication safety issues or compounding quality problems.

Ro, Henry Meds, and MEDVi do not appear to have received similar warning letters as of April 2026, though the regulatory environment for compounded GLP-1 medications is evolving rapidly and all platforms operating in this space face the same fundamental legal framework challenges around shortage list status and “essentially a copy” restrictions.

The broader regulatory picture — covered in detail in our GLP-1 safety and regulatory guide — affects all compounded GLP-1 providers equally. No platform is immune to the possibility that compounded GLP-1 availability could be restricted further through FDA enforcement or court decisions.

Direct Meds Tirzepatide Reviews: What Comparison Shoppers Are Finding

Because tirzepatide is the higher-priced medication option across all platforms, comparison shoppers are particularly focused on value. Direct Meds tirzepatide reviews on Trustpilot are generally consistent with the overall platform rating — patients who received their medication promptly and experienced appetite suppression tend to be satisfied, while the small percentage of negative reviews often cite billing concerns or slower-than-expected results during the titration phase.

The fact that Direct Meds offers both injectable and sublingual tirzepatide at comparable pricing is a differentiator — most competitors either don't offer oral tirzepatide or charge a premium for it. For patients who want to try GLP-1 therapy but have strong needle aversion, having the sublingual option available without a cost penalty removes a real barrier to starting.

Which Platform Fits Which Patient

There's no single best platform — the right choice depends on what you're optimizing for.

If your primary driver is lowest possible monthly cost, Henry Meds' starting price is hard to beat. Understand that you're trading clinical support depth for savings.

If you want transparent all-inclusive pricing with no hidden fees and value having both injectable and oral options, Direct Meds' model is well-suited. The nurse support inclusion adds clinical value that the pricing alone doesn't reflect.

If you prioritize clinical depth and structured follow-up and are willing to pay a premium for it, Ro offers the most thorough clinical infrastructure.

If you're evaluating multiple health categories (weight loss, ED treatment, hair loss) and want a single platform, Hims and MEDVi cover broader service ranges.

Regardless of which platform you choose, the fundamentals don't change: confirm that your provider screens for contraindications thoroughly, understand the distinction between compounded and FDA-approved medications, review cancellation policies before providing payment information, and maintain a relationship with a primary care provider who can monitor your health independently of the telehealth platform.

For the underlying science on how GLP-1 medications work and what realistic outcomes look like, see our guide to GLP-1 weight loss science and hunger hormones. For readers evaluating telehealth cost structures more broadly across treatment categories, our telehealth cost comparison covering TRT platforms applies a similar analytical framework.

MedicalFoundationOfNC.org Editorial Team — This article is for informational purposes only and does not constitute medical advice. All pricing and service information is based on publicly available sources as of April 2026 and is subject to change. This publication has no affiliation with any platform discussed herein. Consult a qualified healthcare professional before starting any medication. If you purchase through any links in this article, a commission may be earned at no additional cost to you.